Positive Outcomes of Denosumab Treatment in 2 Patients With Cherubism.
Journal
Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
ISSN: 1531-5053
Titre abrégé: J Oral Maxillofac Surg
Pays: United States
ID NLM: 8206428
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
10
12
2019
revised:
08
06
2020
accepted:
08
06
2020
pubmed:
11
7
2020
medline:
15
12
2020
entrez:
11
7
2020
Statut:
ppublish
Résumé
Cherubism is a rare autosomal dominant disease whose severity ranges widely, from asymptomatic to life-threatening. Bilateral symmetrical painless expansion of the mandible and maxilla resulting in a typical appearance of the face resembling a cherub, are the highlighted features of the condition. In most cases, cherubism-induced lesions in the jaws appear around the age of 3 years and tend to expand and increase in numbers until puberty. Treatment options for cherubism range from observation to surgical correction and various pharmacologic therapies. Given the excess sensitivity of cherubism osteoclasts to RANKL (receptor activator of nuclear factor κB ligand) and the positive effects of denosumab (XGEVA; Amgen, Thousand Oaks, CA) treatment in patients with giant cell granuloma, we have designed a treatment based on denosumab for 2 cherubism patients that achieves what we consider promising results.
Identifiants
pubmed: 32649899
pii: S0278-2391(20)30590-5
doi: 10.1016/j.joms.2020.06.016
pii:
doi:
Substances chimiques
Denosumab
4EQZ6YO2HI
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
2226-2234Informations de copyright
Copyright © 2020 American Association of Oral and Maxillofacial Surgeons. Published by Elsevier Inc. All rights reserved.